COVID-19 Insights: Pathology, Mechanism, Diagnosis, Treatment Approaches & Novel Anti-Viral Agents

In Wuhan, Hubei Province, China, in December 2019, a novel coronavirus that is now known as SARS-CoV-2 caused a number of acute atypical respiratory illnesses. This virus created a condition known as COVID-19. Human-to-human transmission of the virus has led to a global pandemic. There were no pandemic-causing targeted therapies or methods of diagnosis at the time. After then, standard antibiotics and antiviral treatments were utilised in the treatment. Vaccines for immunisation have been created. In order to respond to the present pandemic quickly, it is essential to evaluate and use the antiviral medications that are currently on the market. Here, we looked at the anti-SARS-CoV-2 drug groups—fusion inhibitors, protease inhibitors, neuraminidase inhibitors, and M2 ion channel protein blockers—that are currently on the market. Clinical trials for these vaccinations and antiviral medications have been running up until this point for total coronavirus immunity. We have complied with permitted and in-development coronavirus vaccines, antiviral drugs, and other drugs.